Cabaletta Bio (CABA)
(Delayed Data from NSDQ)
$4.26 USD
-0.28 (-6.17%)
Updated Sep 6, 2024 03:59 PM ET
After-Market: $4.25 -0.01 (-0.23%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
Cabaletta Bio, Inc. [CABA]
Reports for Purchase
Showing records 1 - 20 ( 45 total )
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Cabaletta Loses Its Halo But We Remain Confident in CABA-201''s Profile; Adjust PT to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
EULAR Recap: Autologous CD19 CAR-T Results Establish Early Benchmarks for Cell Therapies in Autoimmune Diseases
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Initial Data From Myositis and SLE Patients Demonstrate the Promising Potential of CABA-201; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways From Our Conversation With Cabaletta Bio Management; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Top 16 Takeaways From Our Coverage at the H.C. Wainwright Bioconnect Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
1Q Update Confirms CABA-201 Program Is On Track to be First Approval in CAR T for Autoimmune Disease
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Keeping Up with Cabaletta''s Progress; Raise PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
We''re Not Ready to Pump the Brakes on CABA-201; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for CABA 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Target Up to $25 as We Try to Keep Up with Cabaletta
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
All Gas, No Brakes: CABA-201 Clears IND for Study in gMG
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Systemic Sclerosis a Natural Next Indication for CABA-201; Still Just Scratching the Surface
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Opportunity Keeps Getting Bigger and Bigger; PT Up to $17; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Race is On and Cabaletta Takes the Lead; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
CABA-201 Gets Cabaletta?s Undivided Attention; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways From Our Conversation With Cabaletta Bio?s CEO; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
CABA-201 Poised to be First CAR-T in Pivotal Studies for Autoimmune Disease; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Cabaletta?s CARTA Platform to Enter the Clinic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D